ClinicalTrials.gg
RecruitingNCT06715293Hemopill-ProUpdated Apr 22, 2026

A Study to Evaluate the Performance of a Wireless Optical Sensor Capsule in Detection of UGIB

An interventional study of Hemopill and OGD in Melena, Gastrointestinal Bleeding and Hematemesis, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
193
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong — 4 open to participants now, 4 under way, none of them phase 3. Gastrointestinal Hemorrhage · Chinese University of Hong Kong.

Planned enrollment
9th of 15
193 · median 216
Started
2025
the only one that year
No phase
10 of 17
3 open now
Registered
17th of 17
by date

Among the 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 17th registered.

Gastrointestinal Hemorrhage

338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.

Browse Gastrointestinal Hemorrhage studies →

Open to participants now

4 of the 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Upper gastrointestinal bleeding (UGIB) is a common and potentially lethal medical emergency, which requires hospitalization and healthcare resources. Despite the changing epidemiology and advancement of endoscopic therapy in the recent decade, the all-cause mortality of UGIB remains high (>2%). An accurate risk stratification is necessary to triage patients into low- or high-risk groups, in order to inform clinicians for the necessity and timing of urgent endoscopy. However, existing pre-endoscopy risk scores, such as the Glasgow-Blatchford score (GBS), Rockall score and AIMS65 score, are suboptimal in predicting relevant clinical outcomes. An alternative strategy for risk stratification is urgently warranted in patients with UGIB to guide the next step of management.

In a pre-clinical study, the sensitivity and specificity of HemoPill® prototype were 95% and 87.5% respectively, when the sensors were positioned close to the bleeding point. Furthermore, several human clinical studies have proven the feasibility and accuracy of HemoPill® in healthy volunteers and patients with suspected UGIB. Capsule ingestion was well tolerated with no device-related adverse event or capsule retention. All patients with negative HI were found to have no active endoscopic bleeding (true negative, 100%, 17/17). In patients with bleeding >20ml, true positive HI signals were detected (100%, 2/2) In a retrospective multi-center study, 61 patients with suspected UGIB were recruited to use HemoPill®. Among the capsule-positive cases, subsequent endoscopy confirmed active bleeding in 57% (20/35) of them. None of the capsule-negative patients rebled (0%, 0/25), which prevented unnecessary emergent endoscopy in 72% of them (18/25).

Read the detailed description

From December 2023 to February 2024, the investigator conducted a pilot study and screened 51 adult subjects with symptoms and signs of suspected UGIB in Prince of Wales Hospital. Among them, the investigator recruited 20 eligible subjects to receive HemoPill® examination before oesophago-gastro-duodenoscopy (OGD). The overall sensitivity was 80% with a negative predictive value of 87.5%. The area-under-receiver-operating-characteristic curve was 0.633.

The pilot data demonstrated a huge potential for this novel, non-invasive, easy-to-use device as UGIB screening in the real-world. A large-scale, prospective validation study will be conducted to evaluate the diagnostic performance of the new generation HemoPill® acute capsule in UGIB.

03

Conditions studied

  • Melena
  • Gastrointestinal Bleeding
  • Hematemesis

Keywords

  • GIB
  • gastrointestinal bleeding
  • melena
  • per rectal bleeding
  • coffee ground vomiting
  • hematemesis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants have symptoms and signs of suspected UGIB (melena, per rectal bleeding, coffee ground vomiting, prior hematemesis);
  2. Participants will undergo urgent or elective OGD within 24 hours from recruitment;
  3. Written consent obtained.

Exclusion criteria

Exclusion Criteria:

  1. for OGD (e.g. respiratory failure, suspected perforation);
  2. Contraindications for capsule endoscopy (e.g. known gastrointestinal obstruction or stricture, severe dysphagia, impaired consciousness);
  3. Cardiac pacemaker or implanted electromedical devices;
  4. History of gastrectomy or bowel resection;
  5. Ongoing fresh hematemesis requiring emergent endoscopy;
  6. Unstable hemodynamics despite adequate resuscitation requiring emergent endoscopy (i.e. systolic blood pressure \<100mmHg or pulse rate >100 per minute);
  7. Advanced comorbidities (defined as grade 4 or above);
  8. Pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
193 participants (estimated)

Study arms

  • Experimental
    Hemopill to detect the presence of active bleeding in the upper GI tract

    Hemopill to detect the presence of active bleeding in the upper GI tract

    Device: Hemopill · Procedure: OGD

  • Active comparator
    OGD to diagnose and treat active beleeding in the upper GI tract

    ogd will be performed to compare the results with that of the hemopill

    Device: Hemopill · Procedure: OGD

Interventions

  • DeviceHemopill

    Hemopill will be swallowed to detect the presence of active bleeding in the upper GI tract

  • ProcedureOGD

    OGD will be performed to compare the results of the hemopill

06

What researchers measure

Primary outcomes

  1. Presence of active bleeding

    Presence of active bleeding, old blood or potential bleeding sources during OGD examination, which warrants endoscopic haemostatic treatment.

    Time frame: during OGD examination

Secondary outcomes

  1. Technical success rate

    Technical success rate

    Time frame: during OGD examination

  2. Adverse event rate

    Adverse event rate

    Time frame: 30days post study procedure

  3. Capsule retention rate

    Capsule retention rate

    Time frame: 30days post study procedure

  4. Time from Hemopill acute capsule ingestion to a positive HI signal

    Time from Hemopill acute capsule ingestion to a positive HI signal

    Time frame: during OGD examination

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 23 months after the start.

Of 63 non-industry interventional studies with no phase under Gastrointestinal Hemorrhage, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 42. This study's planned 23 months is below that.

Counting every sponsor, half of 73 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2024
First posted
Dec 4, 2024
StartActual
Nov 5, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Apr 30, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06715293
Responsible party
Louis Ho Shing Lau (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Dec 4, 2024
Start date
Nov 5, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Louis HS Lau, FRCP
Contact
louishslau@cuhk.edu.hk
26370428
Felix Sia, MSc
Contact
felixsia@cuhk.edu.hk
852-2637-0428
Louis HS Lau, FRCP
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion